Dapagliflozin initiation in chronic heart failure patients improves central sleep apnoea

Dany Jaffuel; Yannick Bouchaut; Jean-Pierre Mallet; Célia Vidal; Nicolas Molinari; Arnaud Bourdin; François Roubille

doi:10.1183/23120541.00123-2023

Dapagliflozin initiation in chronic heart failure patients improves central sleep apnoea

ERJ Open Res. 2023 Jun 26;9(3):00123-2023. doi: 10.1183/23120541.00123-2023. eCollection 2023 May.

Authors

Dany Jaffuel^{1

2}, Yannick Bouchaut^{2

3}, Jean-Pierre Mallet^{1

2}, Célia Vidal^{4

5}, Nicolas Molinari^{4

5}, Arnaud Bourdin^{1

2}, François Roubille^{2

3}

Affiliations

¹ Department of Pneumology, Arnaud de Villeneuve, Regional University Hospital of Montpellier, Montpellier, France.
² PhyMedExp, University of Montpellier, INSERM U1046, CNRS UMR 9214, Montpellier, France.
³ Department of Cardiology, Arnaud de Villeneuve, Regional University Hospital of Montpellier, Montpellier, France.
⁴ IDESP, INSERM, PreMEdical INRIA, Univ Montpellier, CHU Montpellier, Montpellier, France.
⁵ Groupe Adène, Montpellier, France.

Abstract

Dapagliflozin decreases central sleep apnoea in central sleep apnoea patients, thereby sparing the initiation of ventilatory therapy https://bit.ly/41e2fm0.